These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34830289)

  • 1. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.
    Huang CC; Chou CA; Chen WY; Yang JL; Lee WC; Chen JB; Lee CT; Li LC
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitate aggravates proteinuria-induced cell death and inflammation via CD36-inflammasome axis in the proximal tubular cells of obese mice.
    Li LC; Yang JL; Lee WC; Chen JB; Lee CT; Wang PW; Vaghese Z; Chen WY
    Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1720-F1731. PubMed ID: 30230367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
    Chen Y; Li Y; Wang Y; Wen Y; Sun C
    Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity.
    Byun JH; Lebeau PF; Platko K; Carlisle RE; Faiyaz M; Chen J; MacDonald ME; Makda Y; Yousof T; Lynn EG; Dickhout JG; Krepinsky JC; Weaver F; Igdoura SA; Seidah NG; Austin RC
    Kidney360; 2022 Aug; 3(8):1394-1410. PubMed ID: 36176646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-
    Liu Y; Cheng F; Luo Y; Zhan Z; Hu P; Ren H; Tang H; Peng M
    Biomed Res Int; 2017; 2017():8234507. PubMed ID: 28770225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
    Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
    Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
    BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway.
    Ahn JS; Yang JW; Oh SJ; Shin YY; Kang MJ; Park HR; Seo Y; Kim HS
    BMB Rep; 2021 Jun; 54(6):323-328. PubMed ID: 34078528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice.
    Yang P; Xiao Y; Luo X; Zhao Y; Zhao L; Wang Y; Wu T; Wei L; Chen Y
    J Lipid Res; 2017 Jul; 58(7):1417-1427. PubMed ID: 28536108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mangiferin Improved Palmitate-Induced-Insulin Resistance by Promoting Free Fatty Acid Metabolism in HepG2 and C2C12 Cells via PPAR
    Zhang Q; Kong X; Yuan H; Guan H; Li Y; Niu Y
    J Diabetes Res; 2019; 2019():2052675. PubMed ID: 30809553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
    Ala M; Khoshdel MRF; Dehpour AR
    Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease.
    Hajri T; Zaiou M; Fungwe TV; Ouguerram K; Besong S
    Cells; 2021 May; 10(6):. PubMed ID: 34072832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
    Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
    Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.